Forest Laboratories
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Forest Laboratories sits in the top decile of US sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count).
Forest Laboratories: 145 sponsored US clinical trials, none currently recruiting.
Forest Laboratories sponsors 145 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 127 completed. 100 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 9 trials.
Top-decile sponsor footprint
Forest Laboratories ranks in the top decile of sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
145 total, page 2 of 3
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
NCT01254305
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
NCT01331109
Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections
NCT01281462
Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension
NCT01218100
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
NCT01198795
A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain
NCT01159119
PR-018: An Open-Label, Safety Extension of Study PR-011
NCT01131507
A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
NCT01100606
Long-term Study of Cariprazine in Patients With Schizophrenia
NCT01104792
Safety and Efficacy of Cariprazine in Schizophrenia
NCT01104779
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
NCT01104766
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
NCT01085812
Nebivolol in Patients With Systolic Stage 2 Hypertension
NCT01057251
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
NCT01089790
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
NCT01059539
Safety and Efficacy of Cariprazine for Bipolar I Disorder
NCT01058668
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
NCT01077375
Safety and Efficacy of Cariprazine for Mania
NCT01058096
Safety Study of F2695 SR in Major Depressive Disorder
NCT01034267
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT01034462
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
NCT01016262
Open-label Study of Safety and Tolerability of Memantine in Children With Autism
NCT01999894
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
NCT01014585
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
NCT00990327
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969709
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969150
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone
NCT00970424
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
NCT00948818
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin
NCT00947557
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
NCT00852202
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
NCT00854100
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
NCT00839852
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
NCT00872898
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
NCT00880100
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain
NCT00838799
Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia
NCT00797797
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
NCT00785512
Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia
NCT00793520
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00765999
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
NCT00765882
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
NCT00770861
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
NCT00734630
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
NCT00744237
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
NCT00694707
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
NCT00673790
Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00671073
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
NCT00673075
Escitalopram in Adult Patients With Major Depressive Disorder
NCT00668525
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)
NCT00683592
Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age
NCT00633126
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 34 |
| Phase 3 | 75 |
| Phase 4 | 25 |
How the Forest Laboratories archive is shaped
145 indexed studies, none listed as recruiting (0% open); 127 completed (88%).
Phase mix: 100 late (III/IV) vs 43 early (I/II) (later-stage heavy).
Top condition: Major Depressive Disorder (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Forest Laboratories: archived-pipeline peers nationwide
Peers matched on 145 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Forest Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 145 archived trials
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Forest Laboratories page
145 registered trials is a research-attention snapshot, not an endorsement of Forest Laboratories or any single study.
- None of Forest Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Major Depressive Disorder is the condition Forest Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Forest Laboratories pipeline card: 145 registered trials from official public datasets.Report a data error.